Private company

Savient Pharmaceuticals

Biopharmaceutical company

Savient Pharmaceuticals was a New Jersey–based biopharmaceutical company. Its lead product, pegloticase, was a biologic drug for treatment resistant chronic gout, which it marketed beginning in 2011.³ From Wikipedia, CC BY-SA 4.0

Last updated Oct 19, 2026.

Overview

Industrypharmaceutical industry¹
HeadquartersEast Brunswick¹
Websitewww.savientpharma.com
Listed onNasdaq¹
Incorporated inDE⁴
Business addressOne Tower Center, East Brunswick, Nj 08816⁴

See how the biggest companies compare on our leaderboards

The story

Savient was incorporated in 1980 as Bio-Technology General Corp and changed its name in 2003.

Savient later focused on commercializing pegloticase in the United States and completing the development and seeking regulatory approval in the European Union. The company also sold branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. John H. Johnson was CEO from February 2011 until February 2012, formerly employed by Imclone Systems.

Savient declared bankruptcy in 2013. The drug was selling at $5,390 per vial—around $30,000 for a three-month course of treatment—at the time Savient went under.

Savient was then bought by Crealta. In 2015, Crealta was able to sell the asset to Horizon Pharma for $510 million that year.

From Wikipedia’s article on Savient Pharmaceuticals, shared under CC BY-SA 4.0.⁵

Leadership

Who has led Savient Pharmaceuticals, and when. Pick a name to see everywhere that person has worked.

Chief executive

Louis Ferrari2012–2013

President

Chief financial officer

2010201520202025

Chief executive officerLouis Ferrari Jul 11, 2012 to May 23, 2013⁶
PresidentDavid Veitch Mar 7, 2013 to Mar 7, 2013⁷
PresidentPhilip K. Yachmetz Oct 17, 2013 to Oct 17, 2013⁸
PresidentLouis Ferrari Jul 11, 2012 to May 23, 2013⁶
PresidentPaul Hamelin Dec 10, 2008 to Feb 15, 2011⁹
Chief financial officerKenneth J. Zuerblis Sep 14, 2011 to Feb 13, 2012¹⁰
Chief financial officerDavid Gionco Feb 24, 2009 to Jan 27, 2011¹¹
Chief financial officerBrian J. Hayden Jul 7, 2006 to May 8, 2008¹²

Board members and other officers (26)

Pres, Savient Pharma IrelandDavid Veitch Jan 18, 2012 to Jan 18, 2012¹³
Group VP & Chief Acct OfficerDavid Gionco Jul 25, 2012 to Oct 17, 2013¹⁴
SVP, North American CommericalLouis Ferrari Feb 23, 2011 to May 22, 2012¹⁵
SVP, Chief Medical OfficerKenneth Bahrt Aug 2, 2011 to Oct 17, 2013¹⁶
SVP, Commercial OperationsDavid L. Fink Feb 22, 2006 to Feb 22, 2006¹⁷
SVP, Chief Medical OfficerZebulun D. Horowitz Feb 22, 2006 to Feb 23, 2009¹⁸
SVP, QA/QC, Regulatory AffairsRobert Lamm Feb 24, 2006 to Jan 26, 2009¹⁹
SVP, Commercial OperationsPaul Hamelin May 30, 2006 to Nov 6, 2008²⁰
EVP, Chief Business OfficerPhilip K. Yachmetz Dec 12, 2006 to Nov 6, 2008²¹
Board memberDavid P. Meeker Jan 9, 2013 to Jan 17, 2013²²
Board memberLouis Ferrari Feb 25, 2013 to May 23, 2013²³
Board memberRobert G. Savage Dec 7, 2012 to Dec 7, 2012²⁴
Board memberDavid Y. Norton Sep 6, 2011 to Jul 20, 2012²⁵
Board memberWilliam F. Owen Sep 6, 2011 to May 24, 2012²⁶
Board memberGinger Constantine Jun 11, 2009 to Oct 21, 2013²⁷
Board memberCarl E. Kaplan Jan 3, 2006 to Apr 4, 2006²⁸
Board memberDavid Tendler Jan 3, 2006 to Apr 3, 2007²⁹
Board memberFaye Wattleton Jan 3, 2006 to Apr 3, 2007³⁰
Board memberHerbert J. Conrad Jan 3, 2006 to Jun 10, 2010³¹
Board memberHerbert Weissbach Jan 3, 2006 to Apr 4, 2006³²
Board memberStephen O. Jaeger Jan 3, 2006 to Oct 18, 2013³³
Board memberSurry Jeremy Hayward Jan 3, 2006 to Apr 4, 2006³⁴
Board memberAlan L. Heller May 30, 2006 to Sep 16, 2011³⁵
Board memberJoseph Klein Iii. May 30, 2006 to Jul 21, 2010³⁶
Board memberLee S. Simon May 30, 2006 to May 31, 2011³⁷
General counselPhilip K. Yachmetz Feb 22, 2006 to Mar 7, 2013³⁸

Products and brands

pegloticase

Listed on Wikidata.¹

Former names

BIO TECHNOLOGY GENERAL CORPJun 13, 1995 to Jun 6, 2003⁴

Timeline

Jul 11, 2012New chief executive Louis Ferrari becomes CEO⁶

Sources

The numbers on this page point here. Each one links to the record it came from.

1
WikidataSavient Pharmaceuticals on Wikidata
2
SEC EDGARSavient Pharmaceuticals filings on SEC EDGAR
3
WikipediaSavient Pharmaceuticals on Wikipedia
4
SEC EDGARSavient Pharmaceuticals filings on SEC EDGAR
5
WikipediaSavient Pharmaceuticals on Wikipedia (revision used)
6
SEC EDGARLouis Ferrari, Chief executive officer
7
SEC EDGARDavid Veitch, President
8
SEC EDGARPhilip K. Yachmetz, President
9
SEC EDGARPaul Hamelin, President
10
SEC EDGARKenneth J. Zuerblis, Chief financial officer
11
SEC EDGARDavid Gionco, Chief financial officer
12
SEC EDGARBrian J. Hayden, Chief financial officer
13
SEC EDGARDavid Veitch, Pres, Savient Pharma Ireland
14
SEC EDGARDavid Gionco, Group VP & Chief Acct Officer
15
SEC EDGARLouis Ferrari, SVP, North American Commerical
16
SEC EDGARKenneth Bahrt, SVP, Chief Medical Officer
17
SEC EDGARDavid L. Fink, SVP, Commercial Operations
18
SEC EDGARZebulun D. Horowitz, SVP, Chief Medical Officer
19
SEC EDGARRobert Lamm, SVP, QA/QC, Regulatory Affairs
20
SEC EDGARPaul Hamelin, SVP, Commercial Operations
21
SEC EDGARPhilip K. Yachmetz, EVP, Chief Business Officer
22
SEC EDGARDavid P. Meeker, Board member
23
SEC EDGARLouis Ferrari, Board member
24
SEC EDGARRobert G. Savage, Board member
25
SEC EDGARDavid Y. Norton, Board member
26
SEC EDGARWilliam F. Owen, Board member
27
SEC EDGARGinger Constantine, Board member
28
SEC EDGARCarl E. Kaplan, Board member
29
SEC EDGARDavid Tendler, Board member
30
SEC EDGARFaye Wattleton, Board member
31
SEC EDGARHerbert J. Conrad, Board member
32
SEC EDGARHerbert Weissbach, Board member
33
SEC EDGARStephen O. Jaeger, Board member
34
SEC EDGARSurry Jeremy Hayward, Board member
35
SEC EDGARAlan L. Heller, Board member
36
SEC EDGARJoseph Klein Iii., Board member
37
SEC EDGARLee S. Simon, Board member
38
SEC EDGARPhilip K. Yachmetz, General counsel